Company news

Niagen Bioscience, Inc. news in 2024

Niagen Bioscience, Inc.'s news releases, calls and decks from 2024, newest first.

View company

ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products Category

December 2, 2024

ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide

November 6, 2024

ChromaDex Corporation Reports Third Quarter 2024 Financial Results

October 30, 2024

ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024

October 23, 2024

ChromaDex to Participate in the 17th Annual LD Micro Main Event

October 22, 2024

ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference

September 25, 2024

ChromaDex Appoints Ozan Pamir as Chief Financial Officer

September 19, 2024

ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen® IV and Injection Offerings to Additional Leading Wellness Clinics

September 9, 2024

ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024

August 22, 2024

ChromaDex Secures U.S. Patent for the Composition of Matter of Salt Forms of NMNH (Dihydronicotinamide Mononucleotide), a Precursor to NAD+

August 18, 2024

ChromaDex Corporation Reports Second Quarter 2024 Financial Results

August 6, 2024

ChromaDex to Present at Canaccord Genuity’s 44th Annual Growth Conference

August 4, 2024

ChromaDex to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024

July 23, 2024

ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs)

July 22, 2024

ChromaDex Appoints Carlos Lopez as Senior Vice President, General Counsel

July 21, 2024

ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen® Will Debut at Leading Wellness Clinics in August

July 15, 2024

ChromaDex to Join Russell 2000® Index

June 30, 2024

Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD)

June 23, 2024

ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC)

June 12, 2024

ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT)

June 6, 2024

ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, June 11, 2024

June 3, 2024

ChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

May 22, 2024

ChromaDex’s Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year Award

May 21, 2024

ChromaDex Corporation Reports First Quarter 2024 Financial Results

May 7, 2024

ChromaDex’s NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy Supplement

April 29, 2024

ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe®

April 24, 2024

ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024

April 23, 2024

ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market

April 22, 2024

ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program

March 25, 2024

ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024

February 20, 2024

ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024

February 4, 2024

ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference

January 25, 2024

Calls in 2024

Decks in 2024